Erectile dysfunction (ED) has multifactor pathogenesis, with neurological, vascular,
endocrinological and psychogenic components described. However, about 50-85% of ED …

Background Erectile dysfunction (ED) is a common condition affecting male adults and may
be associated with hypertension, diabetes, hyperlipidemia, and obesity. Phosphodiesterase …

Erectile dysfunction (ED) is defined as the persistent or repeated inability to achieve and/or
maintain an adequate erection to accomplish a complete and satisfactory sexual activity …

Erectile dysfunction (ED) occurs in up to 75% of men with type 2 diabetes (T2DM) and has a
complex pathogenesis owing to a combination of microvascular, macrovascular, endocrine …

DRAMATIC ADVANCES IN THE MANAGEMENT of erectile dysfunction have occurred over
the past decade. Oral therapy with vasoactive agents has emerged as first-line treatment …

Phosphodiesterase type 5 inhibitors (PDE5Is) are the drug of choice for medical
management of erectile dysfunction (ED). On-demand PDE5Is have an overall efficacy of 60 …

Introduction There is a close link between hyperlipidemia/dyslipidemia and erectile
dysfunction (ED), with endothelial dysfunction as a common mechanism. Both ED and …

Patients with cardiovascular disease (CVD) frequently have erectile dysfunction (ED)
because the two conditions have similar risk factors and potential mechanisms. The …

Since the early 1980s, research on the mechanisms of penile erection has done much to
clarify erectile physiology and pathophysiology. More recent studies have identified the …

Important health problems in men such as type 2 diabetes (T2DM), insulin resistance,
erectile dysfunction, benign prostatic hyperplasia and depression have been shown to have …